Author
Yuji Tachimori
Bio: Yuji Tachimori is an academic researcher from National Cancer Research Institute. The author has contributed to research in topics: Lung cancer staging & Lung cancer. The author has an hindex of 4, co-authored 4 publications receiving 2402 citations.
Papers
More filters
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
2,826 citations
Memorial Sloan Kettering Cancer Center1, Keio University2, Beth Israel Deaconess Medical Center3, Mount Sinai Hospital4, Yale University5, Fox Chase Cancer Center6, New Generation University College7, University of Chicago8, New York University9, Imperial College London10, Radboud University Nijmegen11, University of Barcelona12, Peter MacCallum Cancer Centre13, University of Michigan14, University of São Paulo15, Fred Hutchinson Cancer Research Center16, University of Duisburg-Essen17, Northern General Hospital18, University of Caen Lower Normandy19, Churchill Hospital20, Queen's University21, University of Sydney22, Sungkyunkwan University23, Seoul National University24, Kyorin University25, University of Copenhagen26, Nippon Medical School27, Katholieke Universiteit Leuven28, British Hospital29, University of Texas MD Anderson Cancer Center30, University of Antwerp31, Hyogo College of Medicine32, University of Western Australia33, Glenfield Hospital34, Cleveland Clinic35, Icahn School of Medicine at Mount Sinai36, University of Turin37, Université libre de Bruxelles38, Juntendo University39, National Cancer Research Institute40, Mayo Clinic41, Princess Margaret Cancer Centre42, Sinai Grace Hospital43, Netherlands Cancer Institute44, Hiroshima University45, City of Hope National Medical Center46, Georgetown University47, University of Tokushima48, University of Pisa49, Osaka University50
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.
431 citations
TL;DR: An extensive analysis has produced stage classification proposals for lung cancer with a robust degree of discriminatory consistency and general applicability and external validation is encouraged to identify areas of strength and weakness.
182 citations
Columbia University1, Yale University2, Queen's University3, University of Turin4, Georgetown University5, Memorial Sloan Kettering Cancer Center6, Sungkyunkwan University7, University of Tokushima8, University of Pisa9, University of Texas MD Anderson Cancer Center10, Imperial College London11, Osaka University12, University of Antwerp13, Peter MacCallum Cancer Centre14, University of Michigan15, University of São Paulo16, Fred Hutchinson Cancer Research Center17, University of Duisburg-Essen18, University of Caen Lower Normandy19, University of Oxford20, University of Sydney21, Seoul National University22, Kyorin University23, University of Copenhagen24, Nippon Medical School25, Katholieke Universiteit Leuven26, Hyogo College of Medicine27, University of Western Australia28, Glenfield Hospital29, Cleveland Clinic30, Icahn School of Medicine at Mount Sinai31, Université libre de Bruxelles32, Juntendo University33, National Cancer Research Institute34, Mayo Clinic35, Princess Margaret Cancer Centre36, Sinai Grace Hospital37, Netherlands Cancer Institute38, City of Hope National Medical Center39, University of Chicago40, New York University41
TL;DR: An empiric node map is proposed here to establish a universal language for reporting as well as characterize the staging of this disease more accurately and to define node staging as part of a universal stage classification for thymic malignancy.
102 citations
Cited by
More filters
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
2,826 citations
TL;DR: Continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Abstract: Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
2,410 citations
University of Turin1, Aix-Marseille University2, National Health Service3, University Hospital of South Manchester NHS Foundation Trust4, University of Ljubljana5, Karolinska University Hospital6, Centre Hospitalier Universitaire de Grenoble7, University of Aberdeen8, The Royal Marsden NHS Foundation Trust9, VU University Medical Center10, University of Salamanca11, Katholieke Universiteit Leuven12, University Hospital of Lausanne13
TL;DR: The ESMO Guidelines Committee concluded that current state-of-the-art oncology practices in France, Belgium, and the Netherlands are suitable for frontline use and recommend further research into these practices.
2,349 citations
TL;DR: Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged.
2,027 citations
University of Alabama at Birmingham1, University of South Florida2, Vanderbilt University3, City of Hope National Medical Center4, Fox Chase Cancer Center5, University Of Tennessee System6, Brigham and Women's Hospital7, Seattle Cancer Care Alliance8, Case Western Reserve University9, Roswell Park Cancer Institute10, Northwestern University11, Harvard University12, University of Nebraska Medical Center13, University of Utah14, Memorial Sloan Kettering Cancer Center15
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Abstract: Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
1,545 citations